Skip to Content

Generic Zymar Availability

Zymar is a brand name of gatifloxacin ophthalmic, approved by the FDA in the following formulation(s):

ZYMAR (gatifloxacin - solution/drops;ophthalmic)

  • Manufacturer: ALLERGAN
    Approval date: March 28, 2003
    Strength(s): 0.3% [RLD]

Has a generic version of Zymar been approved?

No. There is currently no therapeutically equivalent version of Zymar available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zymar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Aqueous liquid pharmaceutical composition comprised of gatifloxacin
    Patent 6,333,045
    Issued: December 25, 2001
    Inventor(s): Yasueda; Shinichi & Inada; Katsuhiro
    Assignee(s): Senju Pharmaceutical Co., Ltd. Kyorin Pharmaceutical Co., Ltd.

    There is provided an aqueous liquid pharmaceutical composition which comprises Gatifloxacin (chemical nomenclature: (.+-.)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazi nyl)-4-oxo-3-quinoline carboxylic acid) or its salt and disodium edetate. Further, there are provided a method for raising corneal permeability of Gatifloxacin, a method for preventing precipitation of Gatifloxacin crystals, and a method for preventing coloration of Gatifloxacin by incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt.

    Patent expiration dates:

    • August 20, 2019
      Drug product
      Sponsor has requested patent be delisted
    • February 20, 2020
      Pediatric exclusivity

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.